IT1226726B - Composti attivi come inibitori della biosintesi del colesterolo. - Google Patents

Composti attivi come inibitori della biosintesi del colesterolo.

Info

Publication number
IT1226726B
IT1226726B IT8821542A IT2154288A IT1226726B IT 1226726 B IT1226726 B IT 1226726B IT 8821542 A IT8821542 A IT 8821542A IT 2154288 A IT2154288 A IT 2154288A IT 1226726 B IT1226726 B IT 1226726B
Authority
IT
Italy
Prior art keywords
active compounds
biosynthesis inhibitors
cholesterol biosynthesis
cholesterol
inhibitors
Prior art date
Application number
IT8821542A
Other languages
English (en)
Other versions
IT8821542A0 (it
Inventor
Giorgio Bertolini
Cesare Casagrande
Francesco Santangelo
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Spa filed Critical Zambon Spa
Priority to IT8821542A priority Critical patent/IT1226726B/it
Publication of IT8821542A0 publication Critical patent/IT8821542A0/it
Priority to EP19890201957 priority patent/EP0352864A3/en
Priority to US07/385,369 priority patent/US4940800A/en
Priority to JP89197895A priority patent/JPH02250870A/ja
Priority to US07/519,444 priority patent/US5196440A/en
Application granted granted Critical
Publication of IT1226726B publication Critical patent/IT1226726B/it
Priority to US07/719,103 priority patent/US5468746A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IT8821542A 1988-07-28 1988-07-29 Composti attivi come inibitori della biosintesi del colesterolo. IT1226726B (it)

Priority Applications (6)

Application Number Priority Date Filing Date Title
IT8821542A IT1226726B (it) 1988-07-29 1988-07-29 Composti attivi come inibitori della biosintesi del colesterolo.
EP19890201957 EP0352864A3 (en) 1988-07-29 1989-07-25 Compounds active as inhibitors of the cholesterol biosynthesis
US07/385,369 US4940800A (en) 1988-07-29 1989-07-27 Beazimidazole compounds active as inhibitors of the cholesterol biosynthesis
JP89197895A JPH02250870A (ja) 1988-07-28 1989-07-28 コレステロール生合成抑制性化合物
US07/519,444 US5196440A (en) 1988-07-29 1990-05-04 Compounds active as inhibitors of the cholesterol biosynthesis
US07/719,103 US5468746A (en) 1988-07-29 1991-06-21 Compounds active on the cardiovascular system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT8821542A IT1226726B (it) 1988-07-29 1988-07-29 Composti attivi come inibitori della biosintesi del colesterolo.

Publications (2)

Publication Number Publication Date
IT8821542A0 IT8821542A0 (it) 1988-07-29
IT1226726B true IT1226726B (it) 1991-02-05

Family

ID=11183343

Family Applications (1)

Application Number Title Priority Date Filing Date
IT8821542A IT1226726B (it) 1988-07-28 1988-07-29 Composti attivi come inibitori della biosintesi del colesterolo.

Country Status (4)

Country Link
US (1) US4940800A (it)
EP (1) EP0352864A3 (it)
JP (1) JPH02250870A (it)
IT (1) IT1226726B (it)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237792B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
US5387600A (en) * 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
WO1997003970A1 (fr) * 1995-07-17 1997-02-06 Fuji Photo Film Co., Ltd. Composes de benzimidazole
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
US6075040A (en) * 1996-09-05 2000-06-13 Eli Lilly And Company Selective β3 adrenergic agonists
EP0827746B1 (en) 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
SK288117B6 (sk) 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
DE60138535D1 (de) * 2000-02-04 2009-06-10 Children S Hospital Res Founda Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US7317123B2 (en) * 2001-07-06 2008-01-08 Teva Pharmaceutical Industries, Ltd Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation
CA2448917A1 (en) * 2001-07-06 2003-01-16 Reinhold Ohrlein Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3,5-dihydroxy heptanoic acid derivatives, and intermediates thereof
HUP0401014A2 (hu) 2001-07-06 2004-08-30 Teva Pharmaceutical Industries Ltd. Eljárás 7-amino-szin-3,5-dihidroxi-heptánsavszármazékok előállítására, 6-ciano-szin-3,5-dihidroxi-hexánsav származékokon keresztül
ES2375181T3 (es) 2002-05-09 2012-02-27 The Brigham And Women's Hospital, Inc. 1l 1rl-1 como un marcador de enfermedades cardiovasculares.
CA2510319A1 (en) * 2002-12-20 2004-07-15 Thomas J. Smith High pressure compaction for pharmaceutical formulations
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
AU2003283769A1 (en) 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
ES2439229T3 (es) 2004-10-06 2014-01-22 The Brigham And Women's Hospital, Inc. Relevancia de niveles logrados de marcadores de inflamación sistémica tras el tratamiento
NZ560386A (en) * 2005-01-31 2009-12-24 Mylan Lab Inc Pharmaceutical composition comprising hydroxylated nebivolol
NZ563759A (en) 2005-05-31 2010-06-25 Mylan Lab Inc Compositions comprising nebivolol, a hydralazine compound and an isosorbide nitrate
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
CA2659082A1 (en) 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
WO2008026702A1 (fr) 2006-08-30 2008-03-06 Kyushu University, National University Corporation Composition pharmaceutique contenant une nanoparticule de statine encapsulée
CN101686674A (zh) * 2007-03-01 2010-03-31 康考斯保健科学有限责任公司 肌醇烟酸酯的异构体及其用途
TW200849035A (en) 2007-04-18 2008-12-16 Tethys Bioscience Inc Diabetes-related biomarkers and methods of use thereof
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
KR20120139723A (ko) 2010-02-01 2012-12-27 더 호스피탈 포 식 칠드런 재발협착증의 치료 및 예방을 위한 원격 허혈 처치
SG184353A1 (en) 2010-03-31 2012-11-29 Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
JP2013523349A (ja) 2010-04-08 2013-06-17 ザ・ホスピタル・フォー・シック・チルドレン 外傷性損傷に対する遠隔虚血コンディショニングの使用
WO2014022195A1 (en) 2012-08-01 2014-02-06 Tavakoli Zahra Free flowing, frozen compositions comprising a therapeutic agent
CN110575445B (zh) 2013-03-21 2023-08-18 优普顺药物公司美国分部 可注射的持续释放组合物及其用于治疗关节炎症及相关疼痛的方法
AU2016343952A1 (en) 2015-10-27 2018-05-10 Eupraxia Pharmaceuticals Inc. Sustained release formulations of local anesthetics
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2260327A1 (de) * 1972-12-09 1974-06-20 Hoechst Ag Neue carbamidsaeureester
US4434174A (en) * 1980-02-11 1984-02-28 Berlex Laboratories, Inc. Treating cardiovascular diseases with N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4668794A (en) * 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
JPS6322056A (ja) * 1986-04-30 1988-01-29 サンド・アクチエンゲゼルシヤフト オレフイン性化合物の製造法
US4714762A (en) * 1986-10-31 1987-12-22 Warner-Lambert Company Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof

Also Published As

Publication number Publication date
US4940800A (en) 1990-07-10
IT8821542A0 (it) 1988-07-29
JPH02250870A (ja) 1990-10-08
EP0352864A3 (en) 1991-04-03
EP0352864A2 (en) 1990-01-31

Similar Documents

Publication Publication Date Title
IT8821542A0 (it) Composti attivi come inibitori della biosintesi del colesterolo.
FI880031A7 (fi) Anjoniska aendgrupper innehaollande oligomera estrar foer anvaendning som rengoeringsmedel i detergentkompositioner.
FI884924A0 (fi) Humanimmuglobulin som producerats med hybrid-dna-teknik.
FI884063L (fi) Hydrokrackningskatalysatorer och -foerfaranden som anvaender icke-zeolitiska molekylsaoll.
ATE129716T1 (de) Alpha-glukosidase-inhibitoren.
FI880796A7 (fi) Maettade fettsyreamider som inhibitorer av acyl-coa:kolesterol-acyltransferaser.
DK15689A (da) Sukkerethere som blegestabile renseevneforstaerkere.
NO905090D0 (no) Interleukin-1 hemmere.
FI902042A0 (fi) Bencement som innehaoller celltillvaextstimulans.
FI884681A0 (fi) Polyamidbasfoereningar som gjorts eldfasta.
FI885454L (fi) Administrationssystem, som laongsamt frigoer substituerade dihydropyridiner.
FI874917L (fi) Fibermaterial som selektivt absorberar solvaerme.
FI881561A7 (fi) Cellulosabaserade livsmedelshoeljen som innehaoller foernaetade aeggvitefoereningar.
FI880960A0 (fi) Anvaendning av rnas l inhibitor som markeringsaemne i virusinfektioner.
FI884545A7 (fi) Farmaceutisk komposition, som innehaoller avsvaellande piperidinoalkanolfoereningar.
FI885070L (fi) Fotohaerdbar elektrostatisk tryckskiva, som innehaoller elektronacceptor eller -donator.
FI893189A0 (fi) Tetrahaloftalatestrar som brandskyddsvaetskor foer vissa hartser.
DK120388D0 (da) Skab, navnlig badevaerelsesskab
FI883254A0 (fi) Cytostatiskt aktiva antracyklinderivat.
FI894072A0 (fi) Polypeptider anvaendbara som vaccin.
FI884926L (fi) Kopolymerbestrykningskompositioner som innehaoller sulfoalkylmonomeremulsionsmedel.
FI881241L (fi) Laettkonstruktionskaerna, saerskilt som stoedkaerna i skida.
NO872985D0 (no) Inhibitor for polyuretanpropergoler.
FI884154L (fi) Elmaskin, som innefattar slitskilar.
IT211099Z2 (it) Cassetto per mobili.